Evidence map›Paper›PMID 37738537›Full record

ArticleJCO global oncology2023

HIV and Early Treatment Outcomes Among Women With Cervical Cancer Treated With Concurrent Chemoradiation in Tanzania.

Alita Steven Mrema, Mamsau Ngoma, Chacha Josiah, Emmanuel Lugina, Nanzoke Mvungi, Magreth Paul, Evelyne Mkuchika, Emmanuel Nundu, Salama Khamisi Iddy, Eulade Rugengamanzi and 4 more

Abstract read
In one paragraph

Article in JCO global oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alita Steven MremaClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.ORCID 0000-0001-7493-1623
Mamsau NgomaClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.ORCID 0000-0003-1382-8037
Chacha JosiahClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.
Emmanuel LuginaClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.ORCID 0000-0002-9083-4302
Nanzoke MvungiClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.
Magreth PaulClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.
Evelyne MkuchikaClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.ORCID 0000-0003-0285-3237
Emmanuel NunduClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.
Salama Khamisi IddyClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.ORCID 0000-0003-0899-3898
Eulade RugengamanziMuhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.ORCID 0000-0003-0385-3706
Yokobeth Mtambo VuhahulaClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.
Faraja Christopher KiwangaClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.
Charles WoodLouisiana State University Health Sciences Center, New Orleans, LA.
Julius MwaiselageClinical Oncology Department, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.ORCID 0000-0002-0322-9981

Funding

Seroprevalence of COVID-19 of cancer patients in TanzaniaU54CA190155 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI ANGELETTI, PETER C., SOLIMAN, AMR · 2014 to 2022
$4.5M
NCI NIH HHS U54 CA190155
6 · The paper itself

Abstract

purposeCervical cancer (CC) is the leading malignancy in Tanzania. Low-income countries are faced with double epidemics of HIV and CC. This study aimed to investigate how HIV and cancer stage at diagnosis affect early treatment outcomes among women with CC treated with concurrent chemoradiation in Tanzania in the highly active antiretroviral therapy era. MATERIALS AND

methodsThis was a prospective cohort study of patients newly diagnosed with CC at the Ocean Road Cancer Institute from November 2019 to January 2020. The tumor response was assessed using RECIST 3 months post-treatment. The tumor response was categorized as a complete or partial response according to the ultrasound and pelvic examination findings. The univariate and multivariate logistic regression explained the relationship between several covariates (age, stage, HIV status, equivalent dose in 2 Gy fractions, chemotherapy cycles, and treatment time) and treatment response.

resultsA total of 102 patients with CC were included in this study at baseline. After adjusting for other covariates, only completion of treatment within 56 days (odds ratio [OR], 9.23; 95% CI, 1.53 to 55.85;

conclusionEarly treatment response was independent of HIV status. With wide coverage of anitretroviral therapy, patients with HIV can receive radical treatment and have the same early outcomes as their HIV-negative counterparts.

Indexed as

HIV InfectionsUterine Cervical NeoplasmsFemaleHumansProspective StudiesTanzaniaTreatment Outcome

Identifiers

PMID37738537
PMCPMC10581651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.